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With the goal of modeling human disease of the large intestine, we sought to develop an effective protocol for deriving colonic organoids (COs) from differentiated human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs). Extensive gene and immunohistochemical profiling confirmed that the derived COs represent colon rather than small intestine, containing stem cells, transit-amplifying cells, and the expected spectrum of differentiated cells, including goblet and endocrine cells. We applied this strategy to iPSCs derived from patients with familial adenomatous polyposis (FAP-iPSCs) harboring germline mutations in the WNT-signaling-pathway-regulator gene encoding APC, and we generated COs that exhibit enhanced WNT activity and increased epithelial cell proliferation, which we used as a platform for drug testing. Two potential compounds, XAV939 and rapamycin, decreased proliferation in FAP-COs, but also affected cell proliferation in wild-type COs, which thus limits their therapeutic application. By contrast, we found that geneticin, a ribosome-binding antibiotic with translational 'read-through' activity, efficiently targeted abnormal WNT activity and restored normal proliferation specifically in APCmutant FAP-COs. These studies provide an efficient strategy for deriving human COs, which can be used in disease modeling and drug discovery for colorectal disease.
The ability to differentiate hESCs or hiPSCs into colon stem cells could provide a platform for modeling patient-specific gastrointestinal disease. Three-dimensional self-organizing organoids were generated from hESCs and iPSCs, representing intestinal 1 , gastric 2 , brain 3 , liver 4 , lung 5 , and pancreas 6 'mini-organs. ' Although it is possible to generate COs from adult tissue, the derivation from hiPSCs would markedly enhance researchers' capacity to model human colorectal diseases, including cancer.
Through modulation of signaling pathways that are known to regulate normal mouse embryonic development, we developed a stepwise strategy for the progressive generation of definitive endoderm (DE), hindgut endoderm (HE), and subsequently, COs (Fig. 1a) . For efficient generation of DE, we found that culturing hESCs in 3-µM CHIR99021 (a GSK-3β inhibitor) + 100 ng/ml activin A gave rise to more than 95% SRY-box 17 (SOX17) + cells (Supplementary Fig. 1a ). To distinguish colon from small intestine, we reasoned that the regionalization of HE would be required. In mouse embryos, WNT signaling determines posterior fate in a dose-dependent manner by regulating the expression of the posterior marker Cdx2 (ref. 7) . Therefore, we screened WNT-pathway modulators under chemically defined conditions to derive CDX2 + HE cells. To carry out our differentiation protocol in chemically defined conditions, we first tested replacing fetal bovine serum (FBS) with N2, B27 or knockout serum replacement (KOSR)-all commonly used, chemically defined supplements for optimizing cell growth in the absence of serum. B27 was most effective at increasing the percentage of CDX2 + cells, as measured by intracellular flow cytometry (Supplementary Fig. 1b) . Given that glycogen synthase kinase (GSK)-3β lies downstream in the WNT canonical signaling pathway, a panel of ten GSK-3β inhibitors was evaluated for the capacity of each inhibitor to induce CDX2 expression. Treatment with CHIR99021 gave rise to more than 90% CDX2 + cells (Supplementary Fig. 1c ). In addition, CHIR99021 showed a substantially stronger capacity to upregulate the WNTpathway gene AXIN2, as compared to human recombinant protein WNT3A (Supplementary Fig. 1d ). Next, starting on day 8, hindgut (HG) cells were treated with colonic medium containing 3-µM CHIR99021, 300-nM LDN193189 (a small-molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3) and 500 ng/ml epidermal growth factor (EGF) for 12 additional days to l e t t e r S nature medicine VOLUME 23 | NUMBER 7 | JULY 2017 8 7 9 Fig. 1e ), and progressively cavitate into fully convoluted organoids (Fig. 1b,c) .
To test whether these organoids have a colonic phenotype, RTqPCR was used to monitor the relative RNA expression of several colonic markers, including XPNPEP2 (ref. Fig. 1d ). D38 small intestinal spheroids (SISs) and D48 organoids (SIOs), derived using a previously published protocol 1 , were used as controls (Supplementary Table 1 ). Colonic markers were highly expressed in CSs and COs, relative to the SIS and SIO samples. In addition, we further performed immunohistochemistry analysis to confirm the expression of the established colonic markers CA2 (ref. 9), LY6A/E (ref. 7) , and CA4 (ref. 10) in mouse embryonic colon tissue, human colon tissue, and hESC-derived CSs and COs, but not in mouse embryonic small intestine tissue, human duodenum tissue, or hESC-derived SISs and SIOs (Fig. 1e) . The COs adopt typical crypt-like structures, in which proliferative cells at the bottom of the crypts express the marker Ki67 (Fig. 1f) . More than 95% of cells in crypts express CDX2, and around 50% express the pan-differentiation marker keratin 20 (KRT20) (Fig. 1f) . Importantly, many of the cell types found in colonic and intestinal crypts are represented in the COs, including EPH receptor B2 (EPHB2) + transit-amplifying (TA) Marker genes of each sample type were selected such that a gene has at least three times higher expression in that sample type than in the other two sample types. (d) GSEA indicates that hESC-derived COs are significantly enriched for transcripts that are also highly expressed in human colon, whereas hESC-derived SIOs are significantly enriched for transcripts that are also highly expressed in human duodenum. (e) GSEA indicates upregulation of an adult gene set (genes >50-fold upregulated in adult human colon/GSM1698576 versus fetal human colon/GSM1698561) and downregulation of the fetal gene set (genes >50 fold upregulated in fetal human colon/GSM1698561 versus adult human colon/ GSM1698576) in hESC-derived COs. Enriched gene sets were selected according to statistical significance (FDR q < 0.25 and/or P < 0.05).
l e t t e r S nature medicine VOLUME 23 | NUMBER 7 | JULY 2017 8 8 1 cells 11 , villin 1 (VIL1) + epithelial cells 12 , mucin 2 (MUC2) + goblet cells 13 , and chromogranin A (CHGA + ) endocrine cells 14 ( Fig. 1f and Supplementary Fig. 1f ). Different subtypes of endocrine cells were detected, including incretin glucagon-like peptide 1 (GLP1 + ) 15 Lcells and cells expressing tryptophan hydroxylase (TPH1) and the neurotransmitter serotonin (5-HT) 16 ( Fig. 1f) . Of note, we observed the expected proportions of the different cell types that make up the colon epithelium (Fig. 1g) Fig. 1g ). Fig. 1h,i) . The COs were predominantly epithelial, with a minor component of supportive mesodermal tissue; no more than 5% vimentin-positive mesenchymal cells were detected in COs (Supplementary Fig. 1j) . As compared to SIO samples, the transcript levels for Paneth cell markers, including LYZ, REGA, EPHB3, and DEFA5, and small intestine markers, including GATA4 and OSR2, are significantly lower in COs (P < 0.05; Supplementary Fig. 2a) . Lysozyme was readily detected in human duodenum sample but not in hESC-derived COs (Supplementary Fig. 2b ).
To further confirm the colonic identity of the derived COs, we compared the transcription profiles of COs and SIOs by performing RNA sequencing. Colonic markers previously reported in a mouse study 7 are highly expressed in hESC-derived COs, whereas small intestine markers are instead highly expressed in hESC-derived SIOs (Fig. 2a) . Unbiased hierarchical clustering confirmed that hESC-derived COs closely resemble human colon, whereas hESC-derived SIOs closely resemble human duodenum and distal small intestine (Fig. 2b) . Consistently, the genes expressed at relatively higher levels in human duodenum, distal small intestine and human colon followed a similar pattern of expression in hESC-derived SIOs and hESC-derived COs, respectively (Fig. 2c) . Furthermore, gene-set enrichment analysis (GSEA) showed that the gene set highly expressed in human colon is highly enriched in hESC-derived COs (Fig. 2d and Supplementary Fig. 2c) . We also compared the expression profiles of our hESC-derived SIOs and COs with those previously reported for organoids derived from adult human duodenum 24 , ileum 24 , colon 25 , and rectum 24 . hESC-derived COs closely resemble the colon and rectum organoids ( Supplementary  Fig. 2d) . Finally, GSEA suggested that the gene set that was >50-fold upregulated in adult colon relative to fetal colon is highly enriched in hESC-derived COs (Fig. 2e and Supplementary Fig. 2e ). = 3 independent experiments for each condition. P values by unpaired two-tailed Student's t-test: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Center value is the median, and error bars are s.d.
Recently, COs derived from surgically resected human tissue were used to study the pathogenesis of colorectal cancer 26 . Using our defined differentiation paradigm, we sought to use iPSC-derived COs to study the role of genetic factors in the progression of colorectal cancer. FAP is an inherited form of colorectal cancer, caused by mutation of the adenomatous polyposis coli (APC) gene 27 . Therefore, we created iPSCs from individuals with FAP, and we derived COs from FAP-iPSCs. Skin fibroblasts from two individuals with FAP were obtained, one (FAP8) with a 2-bp deletion of APC (4611_4612delAG) leading to a premature termination, and the other (FAP9) harboring a compound mutation: a C>T nonsense mutation (646C>T) resulting in early termination, and a C>T transition (2608C>T) resulting in the substitution of proline 870 with a serine. Fibroblasts were obtained from an age-and gender-matched control to generate iPSCs with wild-type (WT) APC alleles (WT-iPSCs). Fibroblasts were infected with lentivirus expressing OCT4, SOX2, KLF4, and cMYC, and after 2 weeks, iPSC colonies were picked and expanded 28 . These showed typical iPSC colony morphology and expressed pluripotency markers RT-qPCR analysis of WNT-pathway target genes in WT and FAP COs treated with DMSO or geneticin (rapa, rapamycin; XAV, XAV939; Gen, geneticin; n = 3 independent experiments for each condition). P values by unpaired two-tailed Student's t-test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Center value is median, and error bars are s.d. Scale bar, 200 µm.
l e t t e r S nature medicine VOLUME 23 | NUMBER 7 | JULY 2017 (Supplementary Fig. 3a) . Silencing of the viral transgenes in iPSCs was shown by RT-qPCR (Supplementary Fig. 3b) , and the presence of the mutated alleles in FAP-iPSCs was confirmed by using genomic DNA sequencing (Fig. 3a) . Finally, both in vitro differentiation to neurons (ectoderm), DE, and cardiomyocytes (mesoderm) ( Supplementary  Fig. 3c ) and in vivo teratoma formation (Supplementary Fig. 3d ) supported the pluripotency of the iPSCs. Both FAP-iPSC lines harbor one allele with a nonsense mutation that results in early termination of translation. Western blotting was used to measure the expression of APC proteins, which showed decreased expression levels in the FAP-iPSCs as compared to WT controls (Fig. 3b) . Loss of APC is known to enhance cell proliferation 29 , and so we evaluated the expression levels of Ki67 and CCND1 (involved in G1-S phase transition 30 ) to monitor the proliferation rate of iPSCs. In both FAP and WT-iPSCs, essentially all cells are positive for these proliferation markers (Supplementary Fig. 4) . No obvious differences were detected between WT and FAP HE cells for either WNT target gene expression (Supplementary Fig. 5a ) or cell proliferation ( Supplementary Fig. 5b-e) , consistent with relatively high WNT activity and a high proliferation rate, even in WT cells at the HE stage.
WT and FAP HE cells were further differentiated to COs ( Fig. 3c  and Supplementary Fig. 6a ). Western blotting assays confirmed a decreased level of APC protein expression in FAP COs as compared to the WT (Fig. 3d) . In stained sections of WT COs, β-catenin was clearly associated with the plasma membranes as opposed to the nuclei. By contrast, there was significantly enhanced staining for β-catenin in the nucleus of FAP CO cells, consistent with the activation of the WNT pathway ( Fig. 3e and Supplementary Fig. 6b ). RNAsequencing and gene-ontology pathway analyses highlighted the WNT pathway as strongly upregulated in FAP8 (Fig. 3f) and FAP9 (Fig. 3g ) COs relative to WT COs, and genes associated with the WNT pathway were consistently upregulated in both FAP8 and FAP9 COs, as seen by RT-qPCR (Fig. 3h) and Ingenuity Pathway analyses ( Supplementary  Fig. 6c,d) . The nonsense mutation of FAP9 COs results in a shorter, truncated APC protein as compared to the frameshift mutation of FAP8 COs. Given that the length of the APC protein is correlated with WNT activity 31 , the expression levels of WNT target genes were predictably significantly higher in FAP9 COs than in FAP8 COs (Fig. 3h) . Clustering analysis compared WT COs, FAP8 COs, FAP9 COs, normal mucosa samples, and adenomas from patients with FAP. Transcript profiles from WT COs clustered with normal mucosa, and those from FAP COs clustered with FAP adenomas (Supplementary  Fig. 7a ). Gene-ontology pathway analysis found that similar pathways, including the WNT signaling pathway and those associated with colorectal cancer, are upregulated in FAP COs and FAP adenomas (Supplementary Fig. 7b ). GSEA indicates that FAP CO profiles are substantially enriched for transcripts that are also highly expressed in FAP colon adenoma (Supplementary Fig. 7c) . Finally, WT and FAP COs were stained using antibodies to detect the expression of CDX2 and CCND1 (Fig. 3i,j) or of CDX2 and Ki67 (Fig. 3k,l) , and z-stack maximal projections were captured by confocal microscopy and quantified to monitor the proliferation of colonic epithelial cells. Consistent with the activation of the WNT signaling pathway (Fig. 3f-h ), FAP8 and FAP9 COs are composed of a significantly higher percentage of CCND1 + or Ki67 + cells in the population of CDX2 + cells (Fig. 3j,l) , indicating that colonic epithelial cells in FAP organoids have enhanced proliferation capacity, in agreement with the early-stage phenotype of patients with FAP 32 .
A translational goal of disease modeling is to identify drugs that can reverse the pathogenic phenotype. We tested several compounds previously reported to ameliorate tumor-like phenotypes in colorectal cancer, including rapamycin 33 , the Tankyrase inhibitor XAV939 (ref. 34) , and a combination of the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) and the selective COX-2 inhibitor Sulindac 35 . Both XAV939 and rapamycin significantly decreased CDX2 + cell proliferation (Supplementary Fig. 8a,b) . These effective compounds, were then tested in WT and FAP COs. Consistent with the initial assay, the percentages of Ki67 + (Fig. 4a,b) or CCND1 + (Fig. 4c,d ) cells in the CDX2 + cell population of both FAP8 and FAP9 COs were decreased when the cells were treated with 10-µM rapamycin or 5-µM XAV939. RT-qPCR experiments showed that XAV939, but not rapamycin, significantly downregulated transcript levels for WNT target genes (Fig. 4e) . The results suggest that XAV939 functions through a WNT-dependent mechanism, whereas rapamycin functions through a WNT-independent mechanism. However, consistent with the known role of WNT to drive normal colonic epithelial stem cell proliferation, a similar impairment in cell proliferation was observed in WT organoids after exposure to these small molecules (Fig. 4a-d) . This raises concern that rapamycin and XAV939 would not specifically target mutant tumor cells, and thereby, could harm healthy colonic crypts.
Patient-derived FAP IPSCs carry a nonsense mutation that results in an early stop codon. Certain ribosome-binding compounds, such as the aminoglycoside antibiotic G-418 (geneticin), have the capacity to restore the activity of some mutated genes by encouraging the ribosome to 'read through' the premature stop codon, for example, in the APC gene 36, 37 . Western blotting results suggested that 6 µg/ml geneticin fully restores APC protein expression levels in FAP9 iPSCs (Fig. 4f) . A higher dose (25 µg/ml) was required to fully restore APC protein expression in FAP9 COs (Fig. 4g) . Geneticin does not affect APC protein expression levels in WT iPSCs or COs, which suggests that the compound functions through a mutation-specific mechanism. Geneticin-treated FAP9 COs show significantly decreased nuclear β-catenin levels (Supplementary Fig. 8c ), as well as decreased colon epithelial cell proliferation (Fig. 4h-k) . Moreover, geneticin-treated FAP9 COs show significantly decreased WNT target gene expression (Fig. 4l) , but no changes in the levels of the housekeeping gene cyclophilin G (Supplementary Fig. 8d ). The treatment does not affect cell apoptosis, as evaluated by immunostaining for cleaved caspase 3 ( Supplementary  Fig. 8e,f) . Because treatment with geneticin affects neither WNT activity nor cell proliferation in WT COs, this compound could potentially be used to specifically target cellular phenotypes, including hyperproliferation, caused by certain nonsense mutations.
In summary, we established a robust strategy for deriving human COs. By applying this 3D-differentiation strategy to FAP-iPSCs, we developed a 'disease-in-a-dish' platform to monitor the overactivation of WNT signaling associated with the hyperproliferation of colonic epithelial cells, highly relevant to colorectal cancer. A read-through drug, geneticin, could rescue APC protein expression levels, decrease WNT overactivation, and block colonic epithelial cell hyperproliferation specifically in FAP COs, without compromising the normal phenotype of WT COs. In a mouse model, APC restoration promoted cellular differentiation and re-established crypt homeostasis in colorectal cancer 38 , suggesting the translational potential of our CO platform and clinical application of such drug candidates for precision therapy of individuals with colorectal cancer.
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